<code id='F70F6FBBB8'></code><style id='F70F6FBBB8'></style>
    • <acronym id='F70F6FBBB8'></acronym>
      <center id='F70F6FBBB8'><center id='F70F6FBBB8'><tfoot id='F70F6FBBB8'></tfoot></center><abbr id='F70F6FBBB8'><dir id='F70F6FBBB8'><tfoot id='F70F6FBBB8'></tfoot><noframes id='F70F6FBBB8'>

    • <optgroup id='F70F6FBBB8'><strike id='F70F6FBBB8'><sup id='F70F6FBBB8'></sup></strike><code id='F70F6FBBB8'></code></optgroup>
        1. <b id='F70F6FBBB8'><label id='F70F6FBBB8'><select id='F70F6FBBB8'><dt id='F70F6FBBB8'><span id='F70F6FBBB8'></span></dt></select></label></b><u id='F70F6FBBB8'></u>
          <i id='F70F6FBBB8'><strike id='F70F6FBBB8'><tt id='F70F6FBBB8'><pre id='F70F6FBBB8'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:9
          Red Blood Cells
          Adobe

          The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

          The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

          advertisement

          Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Readers respond to H5N1 and livestock movements, and more
          Readers respond to H5N1 and livestock movements, and more

          MollyFergusonforSTATToencouragerobust,good-faithdiscussionaboutdifficultissues,STATpublishesselected

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          UCLA team creates talking throat patch for voice disorders

          AdobeResearchersattheUniversityofCalifornia,LosAngeles,havebuiltasoft,adhesivepatchcapableofturningt